Author:
Hodgson David C.,Mikhaeel N. George
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23(22):5027–33.
2. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-term solid cancer risk among five-year survivors of Hodgkin’s lymphoma. J Clin Oncol. 2007;25(12):1489–97.
3. Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British cohort study. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(10):1568–74.
4. Moser EC, Noordijk EM, van Leeuwen FE, Baars JW, Thomas J, Carde P, et al. Risk of second cancer after treatment of aggressive non-Hodgkin’s lymphoma; an EORTC cohort study. Haematologica. 2006;91(11):1481–8.
5. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Gobbi PG, et al. Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study. Haematologica. 2008;93(9):1335–42.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献